Involvement of cysteinyl leukotrienes in angiotensin II-induced contraction in isolated aortas from transgenic (mRen-2)27 rats

J Hypertens. 2002 Feb;20(2):263-72. doi: 10.1097/00004872-200202000-00016.

Abstract

Objectives: We have previously reported that 5-lipoxygenase-derived products, and particularly the cysteinyl leukotrienes (CysLTs), were involved in angiotensin II (Ang II)-induced contractions in isolated aortas from spontaneously hypertensive rats.

Design: The aim of this study was to assess the role of CysLTs in the vascular response to Ang II in an Ang II-dependent model of hypertension, the (mRen-2)27 transgenic rats (TGs).

Methods: Intact aortic rings from TG and normotensive Sprague-Dawley rats (SDs) were suspended in organ chambers for isometric tension development in response to Ang II. In addition, the release of CysLTs in response to Ang II (0.3 micromol/l) was measured by enzyme immunoassay.

Results: In isolated aortas from TG rats, pretreatment with the 5-lipoxygenase inhibitor (AA861, 10 micromol/l) or the CysLT1 receptor antagonist (MK571, 1 micromol/l) significantly (P < 0.05) reduced Ang II-induced contractions by 52 and 42%, respectively. In addition, Ang II induced a 2.6-fold increase in CysLT release (pg/mg dry weight tissue: 58.3 +/- 17.9 (Ang II, n = 7) versus 22.5 +/- 5.9 (basal, n = 7) P < 0.05), which was inhibited by the AT1 receptor antagonist losartan (1 micromol/l). In contrast, in aortas from SD rats, pretreatment with AA861 or MK571 did not alter Ang II-induced contraction and CysLT production remained unchanged after exposure to Ang II.

Conclusion: These data suggest that CysLTs are involved in the contractile responses to Ang II in isolated aortas from TG but not from SD rats.

Publication types

  • Comparative Study

MeSH terms

  • Angiotensin II / pharmacology*
  • Animals
  • Animals, Genetically Modified / physiology*
  • Aorta / drug effects*
  • Aorta / physiology*
  • Arachidonate 5-Lipoxygenase / immunology
  • Benzoquinones / pharmacology
  • Blood Pressure / physiology
  • Blotting, Western
  • Body Weight / physiology
  • Dose-Response Relationship, Drug
  • Endothelium, Vascular / enzymology
  • Endothelium, Vascular / immunology
  • Leukotriene Antagonists*
  • Lipoxygenase Inhibitors / pharmacology
  • Membrane Proteins*
  • Models, Animal
  • Models, Cardiovascular
  • Muscle Contraction / drug effects
  • Muscle Contraction / physiology
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / enzymology
  • Muscle, Smooth, Vascular / immunology
  • Muscle, Smooth, Vascular / physiology
  • Rats
  • Rats, Inbred SHR / genetics
  • Rats, Sprague-Dawley / genetics
  • Receptors, Leukotriene / biosynthesis
  • Vascular Patency / drug effects
  • Vascular Patency / physiology
  • Vasoconstrictor Agents / pharmacology*

Substances

  • Benzoquinones
  • Leukotriene Antagonists
  • Lipoxygenase Inhibitors
  • Membrane Proteins
  • Receptors, Leukotriene
  • Vasoconstrictor Agents
  • Angiotensin II
  • 2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone
  • cysteinyl leukotriene receptor 2
  • Arachidonate 5-Lipoxygenase
  • leukotriene D4 receptor